ミネソタ州における骨髄異形成症候群の臨床試験
ミネソタ州内の拠点で、骨髄異形成症候群に関する13件の研究が参加者を募集しています。
ミネソタ州内の都市
公式研究テキスト（英語）
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他5件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他8件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Mayo Clinic Rochester, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT05320198The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Masonic Cancer Center, Minneapolis
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/14更新 · NCT06594445Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
75歳以下 · 全性別 · 2026/07/06更新 · NCT05805605A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/10更新 · NCT03017820MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
2歳〜75歳 · 全性別 · 2026/04/16更新 · NCT07493538A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Comprehensive Cancer Center, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT05732103Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
65歳以下 · 全性別 · 2026/01/30更新 · NCT03579875SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/10更新 · NCT06712810Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- University of Minnesota, Minneapolis
被験者募集中第1相
18歳以上 · 全性別 · 2025/04/15更新 · NCT06462365ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。